期刊
NEUROSCIENCE LETTERS
卷 453, 期 3, 页码 195-198出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2009.02.032
关键词
Electroconvulsive therapy; Refractory depression; Brain-derived neurotrophic factor
资金
- CNPq
- FIPE-HCPA
- CAPES
- SMRI
- NARSAD
- Lilly
- Astra Zenica
- Janssen
Refractory depression is a highly debilitating mental condition that originates major social and economic burden. About 50% of the patients experience a chronic course of illness and up to 20% show an insufficient response to drug treatments. Electroconvulsive therapy (ECT) is the most effective treatment method in refractory depression. although its mechanism of action is still unknown. Brain-derived neurotrophic factor (BDNF) is decreased in depressive episodes, and increases with antidepressant treatment, being suggested as a biomarker of response to ECT. We report the findings of a study on the effects of ECT on BDNF and clinical outcomes in a group of drug resistant depressive patients before and after ECT. The patients post-ECTs have shown an important improvement of depressive symptomatology on the HDRS (p = 0.001), of psychotic features on the BPRS (p=0.001)and of the severity of illness on the CGI (p=0.001). There were no changes in the serum BDNF before and after the ECT treatment (p=0.89). These result.; do not support the hypothesis that the clinical improvement following ECT is due to changes in the BDNF. (C) 2009 Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据